Nemaura Medical Launches BEAT™diabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website
November 17 2020 - 8:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces the re-launch of its corporate website,
www.nemauramedical.com, and the website for its flagship program,
BEAT™diabetes, www.beatdiabetes.life, which serves as the
unofficial launch of the program and allows users to register and
learn about participating in an overall health management system to
potentially reverse Type 2 diabetes.
“The launch of the BEAT™diabetes program website is an
important entry into the market to allow consumers to access many
of the life management tools that come with the program. In
addition to introducing the smartphone and tablet app, which will
provide users with our scientifically validated, personalized
coaching driven by our digital platform, it also provides users
with a portal to become among the first to access our non-invasive
glucose monitor, which we expect to launch shortly. We believe that
the combined use of the app with our sugarBEAT® monitor, has the
potential to help reduce diabetes risk and even potentially reverse
Type 2 diabetes with continued and dedicated use. We welcome all
visitors to register for the BEAT™diabetes program and to
experience the benefits of our coaching and monitoring programs to
improve their overall health,” commented Dr. Faz Chowdhury,
Nemaura’s Chief Executive Officer.
“In addition, the re-launch of our corporate website provides
visitors with a more comprehensive view of our company. Previously,
many visitors had equated one of our single products with the
company in general. However, Nemaura is constantly developing its
technology and already has designed multiple products that are in
the process of being refined for regulatory approval and launch.
This new website will give consumers and investors alike a better
view of Nemaura and what we have to offer,” concluded Dr.
Chowdhury.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing
and commercializing non-invasive wearable diagnostic devices. The
company is currently commercializing sugarBEAT® and proBEAT™.
sugarBEAT®, a CE mark approved Class IIb medical device, is a
non-invasive and flexible continuous glucose monitor (CGM)
providing actionable insights derived from real time glucose
measurements and daily glucose trend data, which may help people
with diabetes and pre-diabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and is expected to be launched in the U.S. as a general
wellness product.
The Company sits at the intersection of the global Type 2
diabetes market that is expected to reach nearly $59 billion by
2025, the $50+ billion pre-diabetic market, and the wearable
health-tech sector for weight loss and wellness applications that
is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts may constitute forward-looking statements that are based on
current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, the launch of
proBEAT™ in the US, risks related to regulatory status and the
failure of future development and preliminary marketing efforts,
Nemaura’s ability to secure additional commercial partnering
arrangements, risks and uncertainties relating to Nemaura and its
partners’ ability to develop, market and sell proBEAT™, the
availability of substantial additional equity or debt capital to
support its research, development and product commercialization
activities, and the success of its research, development,
regulatory approval, marketing and distribution plans and
strategies, including those plans and strategies related to both
proBEAT™ digital health, and sugarBEAT®. There can be no assurance
that the company will be able to reach a part of or any of the
global market for CGM with its products/services. The FDA reserves
the right to re-evaluate their decision that proBEAT™ qualifies as
a general wellness product should it become aware of any issues
such as skin irritation or other adverse events from the device, as
well as any misuse impacting patient safety, and any other reason
as the FDA may see fit at its discretion to determine the product
does not fit the definition of a general wellness product. These
and other risks and uncertainties are identified and described in
more detail in Nemaura’s filings with the United States Securities
and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
Contact:
Jules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Sep 2023 to Sep 2024